Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 17, 2022AllergyOpen Access

Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria

View Full Paper
Ask AI
Bookmark
Share

Authors

DTDorothea Terhorst‐MolawiHumboldt-Universität zu BerlinTHTomasz HawroUniversity Medical CenterEGEva GrekowitzHumboldt-Universität zu Berlin

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Terhorst‐Molawi et al. (2022) studied this question.

synapsesocial.com/papers/69d7d01fa2a48916bbbedcabhttps://doi.org/10.1111/all.15585
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of hair shaft progenitors that create a niche for hair pigmentation2017 · 64 citations
  2. 2An improved Peltier effect‐based instrument for critical temperature threshold measurement in cold‐ and heat‐induced urticaria2014 · 55 citations
  3. 3Executive summary of the methods report for ‘The EAACI/GA 2 LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update’2018 · 92 citations
  4. 4Omalizumab in chronic inducible urticaria: a real-life study of efficacy, safety, predictors of treatment outcome and time to response2020 · 3 citations